Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Akari Therapeutics (AKTX)

Akari Therapeutics (AKTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 31,873
  • Shares Outstanding, K 15,857
  • Annual Sales, $ 0 K
  • Annual Income, $ -17,110 K
  • 60-Month Beta -0.83
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.77
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 06/03/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate 0.00
  • Number of Estimates 1
  • High Estimate 0.00
  • Low Estimate 0.00
  • Prior Year -0.16
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.58 +27.22%
on 04/24/20
2.58 -22.09%
on 05/21/20
+0.39 (+24.07%)
since 04/22/20
3-Month
0.87 +131.03%
on 03/16/20
2.58 -22.09%
on 05/21/20
+0.04 (+2.03%)
since 02/21/20
52-Week
0.87 +131.03%
on 03/16/20
3.35 -40.00%
on 08/14/19
-0.40 (-16.60%)
since 05/22/19

Most Recent Stories

More News
Akari Therapeutics Receives Positive EMA Opinion on Orphan Designation for Nomacopan for Bullous Pemphigoid

Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement (C5) and/or leukotriene...

AKTX : 2.01 (+0.50%)
Akari Therapeutics to Participate in STRH Life Sciences Virtual Meeting Series

Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4)...

AKTX : 2.01 (+0.50%)
Akari Therapeutics Announces Positive Topline Results from Fully Recruited Phase II Study of Nomacopan in Bullous Pemphigoid Patients

-- Study achieved primary endpoint of no drug-related serious adverse events and main secondary efficacy endpoints with 7 of the 9 treated patients showing a rapid and clinically significant reduction...

AKTX : 2.01 (+0.50%)
Pharnext Announces the Appointment of David Horn Solomon as Chief Executive Officer

SA (FR0011191287 - ALPHA), an advanced clinical-stage biopharmaceutical company pioneering a new approach to developing innovative drug combinations based on big genomic data and artificial intelligence,...

AKTX : 2.01 (+0.50%)
BNRQY : 2.0000 (+33.33%)
OXNXF : 0.4800 (-11.11%)
SLNCF : 5.5750 (-2.19%)
ZEAL : 34.94 (-0.06%)
Akari Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Business Highlights

Significant Clinical Progress Across Target Indications during 2019 and 2020 Year-to-Date

AKTX : 2.01 (+0.50%)
Akari Therapeutics, Plc Announces Closing of $9.5 Million Private Placement

Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems...

AKTX : 2.01 (+0.50%)
Akari Therapeutics, Plc Announces Private Placement

Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems...

AKTX : 2.01 (+0.50%)
Rexgenero Appoints David Horn Solomon as Chairman

Rexgenero, a regenerative medicine company pioneering the development of advanced cell-based therapies to treat chronic limb-threatening ischemia (CLI), today announces that Dr. David Horn Solomon has...

SLNCF : 5.5750 (-2.19%)
AKTX : 2.01 (+0.50%)
ZEAL : 34.94 (-0.06%)
Akari Therapeutics Announces Preclinical Ophthalmic Data Showing Nomacopan Reduces Both Vascular Endothelial Growth Factor (VEGF) and Retinal Inflammation Supporting Nomacopan as a Potential Treatment Option for Back-of-the-Eye Diseases

Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat autoimmune and inflammatory diseases where the complement and/or leukotriene systems are...

AKTX : 2.01 (+0.50%)
Akari Therapeutics Announces Positive Interim Data from Phase III Paroxysmal Nocturnal Hemoglobinuria (PNH) Study

-- Phase III interim data on the first eight PNH patients who were all transfusion dependent at entry to the CAPSTONE trial show that all four patients randomized to nomacopan were transfusion independent...

AKTX : 2.01 (+0.50%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Trade AKTX with:

Business Summary

Akari Therapeutics PLC is a biopharmaceutical company. It focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. The Company's lead drug consist of Coversin is a recombinant small protein, which acts on complement component-C5,...

See More

Key Turning Points

2nd Resistance Point 2.16
1st Resistance Point 2.09
Last Price 2.01
1st Support Level 1.93
2nd Support Level 1.84

See More

52-Week High 3.35
Fibonacci 61.8% 2.40
Fibonacci 50% 2.11
Last Price 2.01
Fibonacci 38.2% 1.82
52-Week Low 0.87

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar